← 返回

预测实体瘤 CAR-T 治疗结局的混合多尺度模型

英文原题:A hybrid multiscale model for predicting CAR-T therapy outcomes in solid tumors.

查看英文原题

A hybrid multiscale model for predicting CAR-T therapy outcomes in solid tumors.

PubMed 2026/05/23(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤内T细胞的分布(“肿瘤热度”)对免疫治疗成功至关重要。然而,尽管已有多靶点CAR-T 及联合治疗等多种增强肿瘤内T细胞蓄积的策略,但由于对T细胞与微环境相互作用的机制理解有限,进展仍受制约。为此,我们建立了一个具有生理机制的三维肿瘤微环境(TME)模型,用于评估不同环境波动和输注策略下CAR-T 的表现。模型整合了关键血管屏障(滚动、牢固黏附、内皮抑制)和间质屏障(细胞外基质[ECM]密度、代谢竞争、趋化因子敏感性)。模拟结果显示,胶原密度和代谢竞争是决定CAR-T 疗效的主要因素。增强血管滚动和牢固黏附可改善浸润,但仍受胶原和代谢因素限制。内皮抑制显著降低肿瘤热度,而缓解这种抑制可增强应答。全身输注产生的肿瘤热度高于瘤内给药,但联合给药途径或降低胶原密度可恢复疗效,即使在致密肿瘤中亦然。该机制框架可用于合理优化CAR-T 策略。

展开英文摘要原文

T cell distribution within tumors ("tumor hotness") critically determines the success of immunotherapy.

However, despite numerous strategies to enhance intratumoral T cell accumulation - such as multi-target CAR-Ts and combinatorial approaches - limited mechanistic understanding of T cell-microenvironment interactions has constrained progress.

To address this, we developed a mechanistic physiological model of the 3D tumor microenvironment (TME) to evaluate CAR-T performance under environmental fluctuations and across different infusion strategies. The model integrates key vascular (rolling, firm adhesion, endothelial suppression) and interstitial (ECM density, metabolic competition, chemokine sensitivity) barriers.

Our simulations reveal that collagen density and metabolic competition are dominant factors in CAR-T efficacy. Enhancing vascular rolling and firm adhesion improves infiltration but remains limited by collagen and metabolism. Endothelial suppression markedly reduces tumor hotness, while its alleviation enhances response.

Systemic infusion yields higher tumor hotness than intratumoral delivery, but combined routes or reduced collagen density restore efficacy, even in dense tumors. This mechanistic framework enables rational optimization of CAR-T strategies.

论文信息

作者
Nikmaneshi MR、Munn LL
第一作者单位
Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA, 02114, USA.United States
通讯作者单位
Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA, 02114, USA. lmunn@mgh.harvard.edu.United States
期刊
Scientific reports2026 May 23
原文标识
PubMed 42177228 · DOI 10.1038/s41598-026-50412-6